| CRISPR Therapeutics–SEVERAL: investment, 201801 public offering $113.75m of 5m+750k common shares at $22.75/share |
2018-01-03 |
| Indivior–Addex: ADX71441, 201801– license + collab agreem $5m upfront + $4m research funding + $330m milestones plus royalties |
2018-01-03 |
| Central BioHub–in.vent Diagnostica: in vitro diagnostics, 201801 collab existent |
2018-01-02 |
| Clariant–Global Bioenergies: biopolymers, –201801 collab developm bio-based polymers for cosmetics developed w sugar-based isobutene |
2018-01-02 |
| Century Therapeutics–Fujifilm: iPSC technnology, 2018– collab developm iPSC-derived immune effector cells for cancer + license + supply by FDCI |
2018-01-01 |
| CRISPR Therapeutics–ViaCyte: regenerative medicine, 2018– collab incl gene-edited allogeneic stem cell-derived therapies for type 1 diabetes |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–AstraZeneca: oligonucleotide drugs, 2018– collab AstraZeneca is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Biogen: oligonucleotide drugs, 2018– collab Biogen is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–GSK: oligonucleotide drugs, 2018– collab GSK is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–JnJ: oligonucleotide drugs, 2018– collab Janssen is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Pfizer: oligonucleotide drugs, 2018– collab Pfizer is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Roche: oligonucleotide drugs, 2018– collab Roche is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Sanofi: oligonucleotide drugs, 2018– collab Sanofi is founding member of EPOC |
2018-01-01 |
| Exum Instruments–Elemental Scientific: Massbox, 2018– TOFwerk + ESI join as equity partners to design + produce first instrument |
2018-01-01 |
| Exum Instruments–TOFwerk: investment, 2018 TOFwerk + ESI join as equity partners to design + produce first instrument |
2018-01-01 |
| Exum Instruments–TOFwerk: Massbox, 2018– TOFwerk + ESI join as equity partners to design + produce first instrument |
2018-01-01 |
| Pfizer–BioNTech: mRNA-based vaccines, 2018– collab development of influenza vaccines |
2018-01-01 |
| Siemens–OTHER: investment, 2018H1 PLANNED listing of newSiemens Healthineers AG at Frankfurt Stock Exchange |
2018-01-01 |
| BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US |
2017-12-21 |
| Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share |
2017-12-21 |
| Roche–Idorsia: cancer immunotherapy, 201712– collab research + excl license option €15m upfront + €445m milestones plus sales milestones + royalties |
2017-12-20 |
| Boehringer–Autifony: CNS drugs, 201712–202008 collab €25m upfront + €627.5m milestones excl option to KV3.1/3.2 modulators for BI TERMINATED 8/20 |
2017-12-18 |
| Danaher–Cotecna: mass spectrometry, –201712 collab developm LC-MS/MS method for pesticide detection by Sciex + NofaLab |
2017-12-18 |
| Roche–Horizon Discovery: reference standards, 201712– collab developm + supply of FFPE reference standards for ICH-NTRK assays for Roche Dx |
2017-12-18 |
| Fast Track Diagnostics–Siemens: investment, 201712 acquisiton €na of FTD by Siemens Healthineers |
2017-12-15 |
| Evotec–TU Dresden: drug discovery, 201712– collab research €na small-molecule candidates for retinal diseases using iPSC technology with CRTD |
2017-12-13 |
| Flexion Therapeutics–GeneQuine: gene therapy, 201712 acquisition $2m upfront + $62.7m milestones + royalties ww rights to GQ-203 by Flexion |
2017-12-13 |
| NorthSea Therapeutics–BASF: icosabutate, 201712– license from Pronova BioPharma Norge AS |
2017-12-12 |
| NorthSea Therapeutics–SEVERAL: investment, 201712 financing round Series A €25m co-led by Forbion + BGV + incl Novo Seeds + New Science Ventures |
2017-12-12 |
| Oncgnostics–SEVERAL: investment, 201712–201801 crowdfunding campaign €750k via Seedmatch platform |
2017-12-12 |
| AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF |
2017-12-11 |
| Aelin Therapeutics–Boehringer: investment, 201712 financing round Series A totalling €27m incl investor BIVF |
2017-12-11 |
| Aelin Therapeutics–Flanders (govt): investment, 201712 financing round Series A totalling €27m incl investor PMV |
2017-12-11 |
| Aelin Therapeutics–Fund+: investment, 201712 financing round Series A totalling €27m incl investor Fund+ |
2017-12-11 |
| Aelin Therapeutics–Life Sciences Partners: investment, 201712 financing round Series A totalling €27m incl lead investor LSP |
2017-12-11 |
| Aelin Therapeutics–Novartis: investment, 201712 financing round Series A totalling €27m incl investor Novartis Venture Fund |
2017-12-11 |
| Aelin Therapeutics–SEVERAL: investment, 201712 financing round Series A €27m from LSP + PMV + Novartis Venture Fund + BIVF + Fund+ |
2017-12-11 |
| Boehringer–AbeXXa Biologics: drug target research, 201712 collab existent to identify molecular protein targets for cancer |
2017-12-11 |
| Boehringer–Univ California: cancer vaccine, 201712 collab existent to develop vaccine technology platform with UCLA |
2017-12-11 |
| Hookipa–BioMedPartners: investment, 201712 financing round Series C totalling €50m incl returning investor BioMedPartners |
2017-12-11 |
| Hookipa–Boehringer: investment, 201712 financing round Series C totalling €50m incl returning investor BIVF |
2017-12-11 |
| Hookipa–Forbion: investment, 201712 financing round Series C totalling €50m incl returning investor Forbion Capital Partners |
2017-12-11 |
| Hookipa–Gilead: investment, 201712 financing round Series C totalling €50m incl new + strategic investor Gilead |
2017-12-11 |
| Hookipa–HBM: investment, 201712 financing round Series C totalling €50m incl new investor HBM Partners |
2017-12-11 |
| Hookipa–Hillhouse Capital: investment, 201712 financing round Series C totalling €50m incl new investor Hillhouse Capital |
2017-12-11 |
| Hookipa–OTHER: investment, 201712 financing round Series C totalling €50m incl undisclosed US public investment fund as new + lead investor |
2017-12-11 |
| Hookipa–SEVERAL: investment, 201712 financing round Series C €50m led by undisclosed US public investment fund |
2017-12-11 |
| Hookipa–Sirona Capital: investment, 201712 financing round Series C totalling €50m incl new investor Sirona Capital |
2017-12-11 |
| Hookipa–Sofinnova: investment, 201712 financing round Series C totalling €50m incl returning investor Sofinnova Partners |
2017-12-11 |
| Hookipa–Takeda: investment, 201712 financing round Series C totalling €50m incl returning investor Takeda Ventures |
2017-12-11 |
| thinXXS Microtechnology–Idex Corporation: investment, 201712 acquisition of thinXXS Microtechnology AG by Idex Corp |
2017-12-11 |
| PGS.Holland–bio.logis: genetic software, 201712– distribution of bio.logis GIMS in Benelux + Scandinavia + UK by PGS.Holland BV |
2017-12-08 |
| Cell Medica–Coulter Partners: recruitment services, 201712 supply service placement of Annalisa Jenkins as new Board Chair of Cell Medica |
2017-12-07 |
| Hepa Wash–Germany (govt): business development, 201712– supply service support in US with German Accelerator Life Sciences programme |
2017-12-07 |
| Charles River–ERS Genomics: CRISPR technology, 201712– license €na ww non-excl for CRISPR-Cas9 technology to generate modified cell lines |
2017-12-06 |
| Horizon Discovery–ERS Genomics: CRISPR technology, 201712– license ww non-excl expansion |
2017-12-05 |
| Novartis–Medigene: Veregen, 201712– acquisition €na of US rights to Veregen by Fougera Pharmaceuticals Inc |
2017-12-05 |
| Probiodrug–Crossbeta Biosciences: biomarker research, 201712– collab extension developm Alzheimer biomarker to support Probiodrug’s clinical program |
2017-12-05 |
| Probiodrug–MC Services: public relations, 201712 service existent by MC Services |
2017-12-05 |
| Probiodrug–Optimum Strategic Communications: public relations, 201712 service existent by Optimum |
2017-12-05 |
| Probiodrug–Trout Group: public relations, 201712 service existent by The Trout Group |
2017-12-05 |
| Arrowhead–Silence Therapeutics: investment, 201712 DIVESTMENT 2.036m common shares for $7.5m w realised profit of $4.1m |
2017-12-04 |
| Evotec–Ncardia: drug discovery technology, 201712– license ww non-excl €na to access iPSC-derived disease models of Ncardia |
2017-12-04 |
| Institut Virion\Sirion–ExpreS2ion Biotech: expression technology, 201712– collab using ExpreS2 platform for antigen production for IVD tests |
2017-12-04 |
| JnJ–Idorsia: aprocitentan, 201712– collab developm + license ww commerc for Janssen $230m upfront + royalties 20–35% |
2017-12-04 |
| Anaveon–Basel (govt): investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–SEVERAL: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–Univ Zurich: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Roche–Confo Therapeutics: drug discovery services, 201712–202005 collab up to €87.5m plus milestones r+d + commerc small molecule GPCR agonists |
2017-12-01 |
| I-Mab–MorphoSys: antibody cancer drug, 201711– license excl Greater China for MOR202 with $20m upfront + $100m milestones + tiered 2-digit royalties |
2017-11-30 |
| Enyo Pharma–Charles River: drug discovery services, –201711 collab drug target identification of EYP002 using CCMS technology |
2017-11-28 |
| Bitkom–Bayer: digital economy, 201711 Bayer is member of Bitkom w particular focus on digital health + digital farming |
2017-11-27 |
| Boehringer–BioMed X: pharma research, 201711– collab new BioMed X research group in bacterial modulation of innate immunity |
2017-11-27 |
| Geneva Biotech–Sphere Fluidics: genomic technology, 201711– collab to develop large DNA cargo gene deliver + genome engineering systems |
2017-11-27 |
| LIMA project–EU (govt): grant, 201711– Horizon 2020 grant €6.3m 4y Liquid biopsies and IMAging for improved cancer care |
2017-11-23 |
| Arsanis–New Enterprise Associates: investment, 201711 private placement $20m with 2m shares common stock at $10/share |
2017-11-20 |
| Arsanis–SEVERAL: investment, 201711 IPO $46m with 4m+600k shares common stock at $10/share at Nasdaq Global Market |
2017-11-20 |
| Ncardia–SEVERAL: investment, 201711 financing round Series B €10.5m led by new investor Épimède |
2017-11-17 |
| Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche |
2017-11-17 |
| High-Tech Gründerfonds–EWE: investment, 201711 € 7-figure investment in HTGF III fund by EWE AG |
2017-11-16 |
| Laboratoires Réunis–bio.logis: genetic software, 201711 supply use of bio.logis GIMS by Laboratoires Réunis |
2017-11-16 |
| United States (govt)–Molecular Health: drug safety software, 201711–202210 extension collab with CDER for additional 5 years |
2017-11-16 |
| Roche–Arvinas: protein degradation drugs, 201711– strategic license expansion for PROTAC technology to Genentech |
2017-11-15 |
| Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al |
2017-11-15 |
| Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195 |
2017-11-14 |
| Scipio Bioscience–High-Tech Gründerfonds: investment, 201711 seed financing round totalling €1.2m from Quadrivium 1 Seed Fund + HTGF |
2017-11-14 |
| Scipio Bioscience–SEVERAL: investment, 201711 seed financing round €1.2m from Seventure Partners Quadrivium 1 Seed Fund + HTGF |
2017-11-14 |
| Caris Life Sciences–Qiagen: lab automation equipment, 201711 supply QIAsymphony system to Caris Life Sciences |
2017-11-13 |
| CRISPR Therapeutics–CureVac: mRNA technology, 201711– collab + license using RNArt techn to develop in-vivo gene-editing programs in liver diseases |
2017-11-13 |
| InflaRx–SEVERAL: investment, 201711 IPO $100m w 6.667m common shares at $15/share at Nasdaq Global Select Market |
2017-11-10 |
| Ono Pharmaceutical–Neurimmune: drug discovery services, 201711– collab finding mABs against target in neurodegenerative disease using RTM technology |
2017-11-09 |
| Boehringer–MiNA Therapeutics: RNAa drugs, 201711– collab up to €307m plus royalties developm of RNAa drugs for fibrotic liver diseases incl NASH |
2017-11-08 |
| MiNA Therapeutics–MacDougall Biomedical Communications: public relations, 201711 service existent by MacDougall |
2017-11-08 |
| NousCom–5AM Ventures: investment, 201711 financing round Series B totalling €42m incl new + co-investor 5AM Ventures |
2017-11-06 |
| NousCom–Abingworth: investment, 201711 financing round Series B totalling €42m incl new + lead investor Abingworth |
2017-11-06 |
| NousCom–Huntsworth: public relations, 201711 service existent by Citigate Dewe Rogerson |
2017-11-06 |
| NousCom–Life Sciences Partners: investment, 201711 financing round Series B totalling €42m incl returning co-investor LSP |
2017-11-06 |
| NousCom–SEVERAL: investment, 201711 financing round Series B €42m led by new investor Abingworth + incl 5AM Ventures + LSP + Versant Ventures |
2017-11-06 |
| NousCom–Versant Ventures: investment, 201711 financing round Series B totalling €42m incl returning co-investor Versant Ventures |
2017-11-06 |
| Boehringer–Dicerna Pharmaceuticals: RNAi drugs, 201711– collab up to $201m plus royalties developm of RNAi drugs for chronic liver diseases incl NASH |
2017-11-02 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 19 20 21 ... 29 30 31 
Date![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
